Anup Trikannad, Internist in Little Rock, AR, shared a post on X about a paper he co-authored with colleagues published in Blood Cancer Journal:

“New multi-center study alert!

In patients receiving BCMA-directed bispecific antibodies, primary IVIG prophylaxis was linked to:

Better infection-free survival
Improved progression-free and overall survival
Independent predictor of favorable outcomes.”

“Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma”

Authors: Meera Mohan, Aniko Szabo, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi, Binod Dhakal, Anup Trikannad, Samer Al-Hadidi, Anita D’Souza, Nishi Shah, Rajshekhar Chakraborty, Mansi Shah, Carolina Schinke et al.

Anup Trikannad shares findings on IVIG prophylaxis benefits in BCMA-directed bispecific therapy for MM

More posts featuring Anup Trikannad.